Published in final edited form as:

Gen Hosp Psychiatry. 2012 January ; 34(1): 102.e13–102.e14. doi:10.1016/j.genhosppsy.2011.08.014.

Mania following addition of hydroxytryptophan to monoamine oxidase inhibitor

José V. Pardo, M.D., Ph.D.^{a,b,*}

^aDepartment of Psychiatry, University of Minnesota, Minneapolis, MN

^bDirector, Cognitive Neuroimaging Unit, Mental Health Patient Service Line, Minneapolis Veterans Health Care System, Minneapolis, MN

Keywords

monoamine oxidase inhibitor (MAOI); phenelzine; L-5-hydroxytryptophan (5-HTP); L-tryptophan; serotonin syndrome; major depressive disorder (MDD); mania; pharmacotherapy; treatment-resistant depression (TRD)

Introduction

Over-the-counter (OTC) medications/supplements place patients at risk for drug interactions. For example, almost one-third of adults aged 57 through 85 years took at least 5 prescription medications; among prescription medication users, 46% took OTC medications, and 52% took nutritional supplements — placing 4% at risk for major drug-drug interactions [1]. Monoamine oxidase inhibitors (MAOIs) can produce serious interactions. Fear of these prevents judicious use, particularly since MAOIs can frequently offer relief in treatment-resistant major depression disorder (TRD; MDD) [2]. This case shows the likely potential to precipitate mania by addition of L-hydroxytryptophan (5-HTP) to an antidepressant regimen including an MAOI. It highlights the ongoing need to caution patients taking MAOIs, even if sophisticated in biomedical knowledge, about taking adjuvant OTC drugs and nutritional supplements.

Case

This 60-year old engineer, whose son had committed suicide, had TRD and restless legs syndrome. Neither he nor any family member had a history of mania. He had numerous past psychiatric hospitalizations for MDD and was treated with a myriad of modalities often used for TRD. He had steroid-dependent asthma treated with the usual medications and with intermittent brief pulses of prednisone during acute exacerbations.

Two years before this presentation, he developed acute respiratory distress syndrome requiring many weeks in the intensive care unit. Because he relapsed subsequently into a prolonged major depressive episode, phenelzine (MAOI) was selected. He had not tried MAOIs previously, and MAOIs can be useful for TRD [2]. He was instructed about the

*Corresponding author: José V. Pardo, M.D., Ph.D., Minneapolis Veterans Health Care System, Building 68, Suite 235A, One Veterans Drive, Minneapolis, MN 55417, Jose.Pardo@va.gov, Phone: 612-467-3164.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

potential for hypertensive crisis and was given a list of foods to avoid in a tyramine-free diet [3]. His medications (and typical asthma treatments) included phenelzine 75 mg/d; pramipexole 2 mg/d; zolpidem SA 12.5 mg qhs; zolpidem 10 mg qhs; prn prednisone (80 mg decreasing by 10 mg every 3 days); and quetiapine 400 mg/d during tapers. Approximately 4 weeks before admission, he and his wife, a nurse, consulted the internet and read about fibromyalgia and serotonin. Considering the patient might have fibromyalgia, they added 300 mg of 5-hydroxytryptophan (5-HTP) to his medications. They reasoned that unlike tryptophan, produced through fermentation and potentially contraindicated in a tyramine-free diet, 5-HTP was extracted directly from the seeds of *Grifonia simplicifolia* without fermentation. The web information noted the efficacy of 5-HTP combined with MAOIs (pargyline or phenelzine) and the absence of reports of serotonin syndrome induced by 5-HTP.

The patient and spouse noted marked improvement in symptoms of depression immediately upon starting 5-HTP. Less than two weeks later, the spouse called to report she believed the patient was manic. He could not sleep, and his behavior was erratic. He was told to discontinue the 5-HTP and to take the prescribed quetiapine. The spouse noted improvement upon discontinuation of the 5-HTP. However, during an appointment five days later the patient showed grandiosity; pressured speech; derailment; inattentiveness; insomnia; and involvement in many unusual financial concerns. Seven days later, the patient was brought in by the wife because he had developed clear mania and was not manageable at home. He had just terminated a steroid taper begun one month earlier for asthmatic exacerbation. Vital signs included T = 97.5; BP 112/74; P = 94; RR 16. He did not have clonus, but his patellar reflexes were hyperactive. There was no flushing, diaphoresis, or suggestion of delirium. He was admitted to the hospital with diagnosis of probable drug-induced mania, rule-out serotonin syndrome. His laboratory evaluation was unremarkable. Vital signs remained stable, but he remained manic despite tapering phenelzine and increasing quetiapine. The patient was uncooperative but not violent. After improving somewhat, he left the hospital against medical advice not having evidenced imminent risk to himself or others.

Discussion

Many patients believe in alternative medicine and OTC treatments. The widespread availability and use of the internet enables patients' ready access to information of uncertain timeliness and credibility as well as exploitation by OTC industry. Patients get tempted to become their own doctors.

L-tryptophan, an essential amino acid, has been used as an OTC supplement to treat a myriad of conditions: insomnia, depression, anxiety, fibromyalgia; etc. However in 1989, an epidemic of eosinophilia-myalgia syndrome from contaminants in tryptophan supplements involved 1,531 cases and 27 deaths [4]. For a period afterward, the sale of tryptophan was prohibited. Tryptophan supplementation became risky and was replaced by 5-HTP as the preferred supplement.

5-HTP, metabolized from tryptophan via hydroxylation, freely crosses the blood brain barrier and gets converted to serotonin by aromatic L-amino-acid decarboxylase. This patient took 5-HTP for several reasons: 1) He remained symptomatic with depression. 2) 5-HTP was not on his list of foods to avoid in a tyramine-free diet. 3) 5-HTP, unlike tryptophan, was not produced by fermentation, a process he knew might contain tyramine contraindicated for someone taking an MAOI. 4) The lay literature suggested 5-HTP was not associated with the serotonin syndrome.

The differential diagnosis included serotonin syndrome and drug-induced mania (MAOI vs. steroid vs. 5-HTP). The combination of tryptophan or 5-HTP with MAOIs can cause a serotonin syndrome/neurotoxicity [5,6]. Furthermore, the combination of 5-HTP with MAOIs or SSRIs in rat models can produce a malignant serotonin syndrome [7,8]. Although this patient had hyper-reflexia, he had no other signs or symptoms of serotonin syndrome. Therefore, his provisional diagnosis was drug-induced mania.

Potential culprits for mania were his phenelzine, steroid taper, or 5-HTP. The patient remained depressed on phenelzine. He had just completed a prednisone taper and had numerous prior tapers with quetiapine coverage without mania. The timing of the euphoric mood immediately after starting 5-HTP suggests it was at least a partial precipitant of mania. The “Newcastle cocktail” that combines MAOI, serotonin, and lithium is known to have antidepressant effects in severe TRD [9]. Two cases have been reported of inducing hypomania with tryptophan in combination with MAOI [10]. Unlike the present case, we found no reported cases of mania in the setting of 5-HTP added to an MAOI. Clinicians need be alert to such a possibility and emphasize the dangers of OTC supplements especially adjuvant to MAOIs.

References

1. Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. *JAMA*. 2008; 300:2867–78. [PubMed: 19109115]
2. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. *Neuropsychopharmacology*. 1995; 12:185–219. [PubMed: 7612154]
3. Gardner DM, Shulman KI, Walker SE, Taylor SA. The making of a user friendly MAOI diet. *J Clin Psychiatry*. 1996; 57:99–104. [PubMed: 8617704]
4. Swygert LA, Maes EF, Sewell LE, et al. Eosinophilia-myalgia syndrome. Results of national surveillance. *JAMA*. 1990; 264:1698–703. [PubMed: 2398610]
5. Alvine G, Black DW, Tsuang D. Case of delirium secondary to phenelzine/l-tryptophan combination. *J Clin Psychiatry*. 1990; 51:311. [PubMed: 2365671]
6. Pope HG Jr, Jonas JM, Hudson JI, Kafka MP. Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan. *Am J Psychiatry*. 1985; 142:491–2. [PubMed: 3976924]
7. Ma Z, Zhang G, Jenney C, Krishnamoorthy S, Tao R. Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats. *European Journal of Pharmacology*. 2008; 588:198–206. [PubMed: 18499101]
8. Izumi T, Iwamoto N, Kitaichi Y, et al. Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats. *European Journal of Pharmacology*. 2006; 532:258–64. [PubMed: 16488409]
9. Barker WA, Scott J, Eccleston D. The Newcastle chronic depression study: Results of a treatment regime. *Int Clin Psychopharmacol*. 1987; 2:261–72. [PubMed: 3121718]
10. Goff DC. Two cases of hypomania following the addition of l-tryptophan to a monoamine oxidase inhibitor. *Am J Psychiatry*. 1985; 142:1487–8. [PubMed: 4073318]